OZTA Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.00 |
| 52 Week High | €15.37 |
| 52 Week Low | €6.59 |
| Beta | 0.69 |
| 11 Month Change | 12.54% |
| 3 Month Change | 27.40% |
| 1 Year Change | -12.49% |
| 33 Year Change | -36.78% |
| 5 Year Change | -63.95% |
| Change since IPO | 335.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| OZTA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.5% | -0.02% | -1.5% |
| 1Y | -12.5% | -17.7% | 7.9% |
Return vs Industry: OZTA exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: OZTA underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| OZTA volatility | |
|---|---|
| OZTA Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OZTA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OZTA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,000 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
| OZTA fundamental statistics | |
|---|---|
| Market cap | €6.90b |
| Earnings (TTM) | €161.49m |
| Revenue (TTM) | €7.01b |
45.9x
P/E Ratio1.1x
P/S RatioIs OZTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OZTA income statement (TTM) | |
|---|---|
| Revenue | €7.01b |
| Cost of Revenue | €4.26b |
| Gross Profit | €2.75b |
| Other Expenses | €2.58b |
| Earnings | €161.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 39.18% |
| Net Profit Margin | 2.31% |
| Debt/Equity Ratio | 123.2% |
How did OZTA perform over the long term?
See historical performance and comparison